{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:48:02Z","timestamp":1793908082269,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2020JJ4072"],"award-info":[{"award-number":["2020JJ4072"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2019JJ40230"],"award-info":[{"award-number":["2019JJ40230"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["B2019034"],"award-info":[{"award-number":["B2019034"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["B2019035"],"award-info":[{"award-number":["B2019035"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Bempedoic acid is a new drug that reduces cholesterol synthesis via inhibiting ATP citrate lyase. It remains unclear whether the combination of bempedoic acid and other lipid-lowering drugs is better than these drugs alone. This study systematically reviewed the efficacy and safety of bempedoic acid monotherapy or combination togethers in hypercholesterolemic patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Randomized controlled trials were searched across Medline, Embase, Cochrane library, web of science, etc. The net change scores [least squares mean (LSM) percentage change] in LDL-C level were meta-analyzed using weighted mean difference. The reductions in other lipids including total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein (ApoB) and high sensitivity C reactive protein (hsCRP) were also assessed. Odds ratio (OR) of the incidence of adverse events (AEs) were calculated to evaluate the safety of bempedoic acid.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 13 trials (4858 participates) were included. Pooled data showed that the combination togethers resulted in greater reductions in LDL-C level than monotherapies (bempedoic acid + statin vs. statin: LSM difference (%), \u2212\u200918.37, 95% CI, \u2212\u200920.16 to \u2212\u200916.57, I<jats:sup>2<\/jats:sup>\u00a0=\u20090; bempedoic acid + ezetimibe vs. ezetimibe: LSM difference (%), \u2212\u200918.89, 95% CI, \u2212\u200929.66 to \u2212\u20098.13, I<jats:sup>2<\/jats:sup>\u00a0=\u200987%). But the difference in efficacy between bempedoic acid and ezetimibe was not obvious. Meta-regression analysis showed the treatment duration was a source of heterogeneity (adj R<jats:sup>2<\/jats:sup>\u2009=\u200916.92, 95% CI, 0.04 to 0.72). Furthermore, the background therapy of statin before screening decreased the efficacy of bempedoic acid. In addition, bempedoic acid also resulted in a significant reduction in TC, non-HDL-C, ApoB and hsCRP level. The OR of muscle-related AEs by the combination of bempedoic acid and statin was 1.29 (95% CI, 1.00 to 1.67, I<jats:sup>2<\/jats:sup>\u00a0=\u20090) when compared with statin alone.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This study showed the efficacy of combination togethers were similar but stronger than these drugs alone. Of note, a trend of high risk of muscle-related AEs by the combination of bempedoic acid and statin was observed, though it is not statistically significant, such risk is needed to be confirmed by more trials, because it is important for us to determine which is the better combinative administration for statin-intolerant patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s40360-020-00463-w","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T12:04:34Z","timestamp":1607083474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"21","author":[{"given":"Xiang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xubiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxiang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanglu","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5984-4924","authenticated-orcid":false,"given":"Chengfeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"463_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38:2459\u201372.","journal-title":"Eur Heart J"},{"key":"463_CR2","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol. 2017;70:1785\u2013822.","journal-title":"J Am Coll Cardiol"},{"key":"463_CR3","doi-asserted-by":"crossref","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E and Sabatine MS. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. Jama. 2016;316:1289\u201397.","DOI":"10.1001\/jama.2016.13985"},{"key":"463_CR4","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"7","author":"SL Pinkosky","year":"2016","unstructured":"Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457.","journal-title":"Nat Commun"},{"key":"463_CR5","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","volume":"380","author":"BA Ference","year":"2019","unstructured":"Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2019;380:1033\u201342.","journal-title":"N Engl J Med"},{"key":"463_CR6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/eurheartj\/ehx462","volume":"39","author":"BA Ference","year":"2018","unstructured":"Ference BA. How to use Mendelian randomization to anticipate the results of randomized trials. Eur Heart J. 2018;39:360\u20132.","journal-title":"Eur Heart J"},{"key":"463_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccl.2017.12.007","volume":"36","author":"A Saeed","year":"2018","unstructured":"Saeed A, Ballantyne CM. Bempedoic acid (ETC-1002): a current review. Cardiol Clin. 2018;36:257\u201364.","journal-title":"Cardiol Clin"},{"key":"463_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","volume":"15","author":"BB Adhyaru","year":"2018","unstructured":"Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol. 2018;15:757\u201369.","journal-title":"Nat Rev Cardiol"},{"key":"463_CR9","doi-asserted-by":"crossref","unstructured":"Bouitbir J, Sanvee GM, Panajatovic MV, Singh F and Kr\u00e4henb\u00fchl S. Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacol Res. 2020;154:104201.","DOI":"10.1016\/j.phrs.2019.03.010"},{"key":"463_CR10","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/S0735-1097(20)32560-2","volume":"75","author":"AFG Fernandes","year":"2020","unstructured":"Fernandes AFG, Knijnik LM, Maza MR, Penalver J, Cardoso R, Alfonso CE, et al. A meta-analysis of bempedoic acid for dyslipidemia in statin-intolerant patients. J Am Coll Cardiol. 2020;75:1933.","journal-title":"J Am Coll Cardiol"},{"key":"463_CR11","doi-asserted-by":"crossref","unstructured":"Wang X, Luo S, Gan X, He C, Huang R. Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials. Kardiol Pol. 2019;77:207\u201316.","DOI":"10.5603\/KP.a2019.0013"},{"key":"463_CR12","first-page":"1.13907","volume":"140 supplement","author":"KMU KSU","year":"2019","unstructured":"KSU KMU, Khan M, Lone AN, Valavoor S, Raghu C, Arshad A, et al. Meta analysis of efficacy and safety of bempedoic acid in lowering low density lipoprotein cholesterol. Circulation. 2019;140 supplement:1.13907.","journal-title":"Circulation"},{"key":"463_CR13","unstructured":"Higgins JJGS. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated march 2011]: The Cochrane Collaboration; 2011. Available from www.cochrane-handbook.org.2011."},{"key":"463_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12944-019-0994-7","volume":"18","author":"C Qiu","year":"2019","unstructured":"Qiu C, Zhao X, She L, Shi Z, Deng Z, Tan L, et al. Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2019;18:54.","journal-title":"Lipids Health Dis"},{"key":"463_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"463_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315:629\u201334.","journal-title":"Bmj."},{"key":"463_CR17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of Bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022\u201332.","journal-title":"N Engl J Med"},{"key":"463_CR18","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of Bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. Jama. 2019;322:1780\u20138.","journal-title":"Jama."},{"key":"463_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","volume":"13","author":"ND Lalwani","year":"2019","unstructured":"Lalwani ND, Hanselman JC, MacDougall DE, Sterling LR, Cramer CT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial. J Clin Lipidol. 2019;13:568\u201379.","journal-title":"J Clin Lipidol"},{"key":"463_CR20","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.atherosclerosis.2019.06.020","volume":"287","author":"C Ballantyne","year":"2019","unstructured":"Ballantyne C, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Efficacy and safety of Bempedoic acid + Ezetimibe fixed-dose combination in patients at high CVD risk and with elevated LDL-C receiving maximally tolerated statin therapy. Atherosclerosis. 2019;287:e7\u20138.","journal-title":"Atherosclerosis."},{"key":"463_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of Bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8:e011662.","journal-title":"J Am Heart Assoc"},{"key":"463_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","volume":"277","author":"CM Ballantyne","year":"2018","unstructured":"Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195\u2013203.","journal-title":"Atherosclerosis."},{"key":"463_CR23","doi-asserted-by":"crossref","unstructured":"McGowan M, MacDougall D, Hanselman J, Watling S and Lalwani N. Bempedoic acid reduces LDL-C and is well-Tolerated in patients receiving atorvastatin 80 mg background therapy. J Clin Lipidol. 2017;11:838.","DOI":"10.1016\/j.jacl.2017.04.107"},{"key":"463_CR24","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","volume":"10","author":"PD Thompson","year":"2016","unstructured":"Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016;10:556\u201367.","journal-title":"J Clin Lipidol"},{"key":"463_CR25","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.amjcard.2016.03.043","volume":"117","author":"CM Ballantyne","year":"2016","unstructured":"Ballantyne CM, McKenney JM, MacDougall DE, Margulies JR, Robinson PL, Hanselman JC, et al. Effect of ETC-1002 on serum low-density lipoprotein cholesterol in Hypercholesterolemic patients receiving statin therapy. Am J Cardiol. 2016;117:1928\u201333.","journal-title":"Am J Cardiol"},{"key":"463_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","volume":"9","author":"PD Thompson","year":"2015","unstructured":"Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9:295\u2013304.","journal-title":"J Clin Lipidol"},{"key":"463_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacl.2014.02.069","volume":"8","author":"RS Newton","year":"2014","unstructured":"Newton RS, Ballantyne CM, Thompson PD, MacDougall DE, Hanselman JC, Margulies JR, et al. ETC-1002 lowers LDL-cholesterol and is well tolerated in Hypercholesterolemic patients across four phase 2a studies. J Clin Lipidol. 2014;8:339\u201340.","journal-title":"J Clin Lipidol"},{"key":"463_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","volume":"34","author":"MJ Gutierrez","year":"2014","unstructured":"Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34:676\u201383.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"463_CR29","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"CM Ballantyne","year":"2013","unstructured":"Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62:1154\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"463_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.phrs.2018.12.010","volume":"141","author":"R Tabrizi","year":"2019","unstructured":"Tabrizi R, Tamtaji OR, Mirhosseini N, Lankarani KB, Akbari M, Dadgostar E, et al. The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019;141:85\u2013103.","journal-title":"Pharmacol Res"},{"key":"463_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/cvr\/cvy293","volume":"115","author":"J Tunon","year":"2019","unstructured":"Tunon J, Badimon L, Bochaton-Piallat ML, Cariou B, Daemen MJ, Egido J, et al. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovasc Res. 2019;115:10\u20139.","journal-title":"Cardiovasc Res"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00463-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-020-00463-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00463-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T12:30:11Z","timestamp":1607085011000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-020-00463-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["463"],"URL":"https:\/\/doi.org\/10.1186\/s40360-020-00463-w","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}